PDS Biotechnology Story

<div class='circular--portrait' style='background:#FF01C9;color: #FFF8DC;font-size:4em;'>PB</div>
PDSB -- USA Stock  

USD 2.73  0.10  3.80%

It appears PDS Biotechnology will continue to recover much faster as its share price surged up 27.14% today. PDS Biotechnology's current daily volatility is 6.41 percent, with a beta of -0.49 and an alpha of 0.05 over DOW. As many baby boomers are still indifferent towards saving accounts, it makes sense to go over PDS Biotechnology. What exactly are PDS Biotechnology shareholders getting in January?
Published over a month ago
View all stories for PDS Biotechnology | View All Stories
Is PDS Biotechnology (NASDAQ:PDSB) a new disruptor?
The company conducts business under Healthcare sector and is part of Biotechnology industry. On a scale of 0 to 100, PDS Biotechnology holds a performance score of 5. The company holds a Beta of -0.4937, which implies possible diversification benefits within a given portfolio. Let's try to break down what PDS Biotechnology's beta means in this case. As returns on the market increase, returns on owning PDS Biotechnology are expected to decrease at a much lower rate. During the bear market, PDS Biotechnology is likely to outperform the market. Although it is vital to follow PDS Biotechnology current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. The approach into forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for PDS Biotechnology, which you can use to evaluate the performance of the company. Please employ PDS Biotechnology expected short fall, and the relationship between the value at risk and daily balance of power to make a quick decision on whether PDS Biotechnology historical price patterns will revert.
Investing in PDS Biotechnology, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding PDS Biotechnology along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of PDS Biotechnology's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of PDS Biotechnology in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as PDS Biotechnology. Your research has to be compared to or analyzed against PDS Biotechnology's peers to derive any actionable benefits. When done correctly, PDS Biotechnology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in PDS Biotechnology.

How important is PDS Biotechnology's Liquidity

PDS Biotechnology financial leverage refers to using borrowed capital as a funding source to finance PDS Biotechnology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. PDS Biotechnology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between PDS Biotechnology's total debt and its cash.

How PDS Biotechnology utilizes its cash?

To perform a cash flow analysis of PDS Biotechnology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash PDS Biotechnology is receiving and how much cash it distributes out in a given period. The PDS Biotechnology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

PDS Biotechnology Correlation with Peers

Investors in PDS Biotechnology can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in PDS Biotechnology. Diversification will allow for the same portfolio return with reduced risk. The correlation table of PDS Biotechnology and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities PDS Biotechnology is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of PDS Biotechnology for more details

Acquisition by Van Voorhees Seth of 202800 shares of PDS Biotechnology subject to Rule 16b-3

Legal trades by PDS Biotechnology insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
PDS Biotechnology insider trading alert for grant of stock option (right to buy) by Van Voorhees Seth, Chief Financial Officer, on 6th of January 2021. This event was filed by Pds Biotechnology Corp with SEC on 2021-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down PDS Biotechnology Further

PDS Biotechnology appears to be very risky, given 1 month investment horizon. PDS Biotechnology maintains Sharpe Ratio (i.e. Efficiency) of 0.0825, which implies the firm had 0.0825% of return per unit of standard deviation over the last month. Our approach into forecasting the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. By inspecting PDS Biotechnology technical indicators you can now evaluate if the expected return of 0.53% is justified by implied risk. Please employ PDS Biotechnology market risk adjusted performance of 0.0555, and Risk Adjusted Performance of 0.0053 to confirm if our risk estimates are consistent with your expectations.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Over 3 percent rise for PDS Biotechnology. What does it mean for investors?

Current Jensen Alpha is up to 0.05. Price may slip again. PDS Biotechnology exhibits very low volatility with skewness of 0.57 and kurtosis of 1.24. However, we advise investors to further study PDS Biotechnology technical indicators to make sure all market info is available and is reliable.

Our Conclusion on PDS Biotechnology

Whereas some other companies under the biotechnology industry are still a bit expensive, PDS Biotechnology may offer a potential longer-term growth to investors. On the whole, as of the 4th of December 2020, our analysis shows that PDS Biotechnology almost neglects market trends. The company is undervalued and projects very low odds of financial turmoil for the next 2 years. However, our up-to-date 30 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of PDS Biotechnology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com